While ATM, BRCA, and POLQ mutations were similarly prevalent in both cancer types, adenocarcinoma patients had a high frequency to mutations effecting FANCM (8.9%) and FANCD2 (5.6%), comprising a majority of the difference between the two cancers in overall HR mutation rate (Table 5). This evidence concerns the gene FANCD2 and adenocarcinoma.